RGT 2.90% 35.5¢ argent biopharma limited

Ann: Appointment of UK Lead Broker Change of Company Secretary, page-2

  1. 14,010 Posts.
    lightbulb Created with Sketch. 2383
    VERY Interesting. Certainly a move to maybe just have the UK listing in the future.

    Probably can't raise any more funds from Australian shareholders - there probably aren't that many left - so they will be targeting UK investors who still believe MXC is a solid investment and don't know the history of the company.

    MXC don't even try to hide these quite blatant moves anymore.

    MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’) is pleased to announce the
    appointment of UK based Peterhouse Capital as the Company’s lead broker on the LSE, with
    immediate effect, replacing Turner Pope. This appointment is part of the Company’s UK focused
    corporate strategy with respect to future equity capital market financings and corporate
    opportunities.

    The Company also advises that Mr David Lim, MGC Pharma’s Company Secretary, has retired from
    the position. Mr Lim has overseen the transition of the Company's corporate compliance structure
    to one that is significantly more organised and well positioned for the future.
    Mr Lim is replaced as MGC’s Company Secretary by Messrs Rowan Harland and Arron Canicais of
    SmallCap Corporate Pty Ltd, a Perth based corporate advisory firm, who have been appointed Joint
    Company Secretaries effective today.
    MGC’s non-executive chairman, Mr Brett Mitchell, commented “The board is very pleased to
    welcome the appointment of Peterhouse Capital as lead broker for the LSE to play a key role in the
    company’s future funding strategies and corporate opportunities. In addition, we would also like to
    thank Mr David Lim for his dedication and commitment to the Company, and the board wishes him
    every success with his next venture.”
    --Ends--
 
watchlist Created with Sketch. Add RGT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.